Study summary · research use only
Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study used in silico modelling and in vitro experiments in human cancer cell lines to investigate ibutamoren (IBU) as a potential inhibitor of the MDM2-p53 interaction. Molecular modelling indicated a low IC50 for IBU binding to the p53-binding pocket of MDM2. In vitro, IBU treatment reduced viability of cell lines with a functional MDM2-p53 pathway but not in lines carrying damaging pathway mutations, and RT-qPCR showed differential expression of two p53 target genes under IBU treatment only in cell lines with wild-type MDM2-p53 pathways. The authors describe these as preliminary findings supporting further study of IBU's mechanism of action and potential development in oncology research.
Abstract
The MDM2-p53 pathway plays a pivotal role in regulating cell cycle and apoptosis, with its dysfunction contributing to approximately 50% of human malignancies. MDM2, an E3 ubiquitin ligase, targets the tumour suppressor p53 for degradation, thereby promoting uncontrolled cell growth in cancers. Inhibiting the MDM2-p53 interaction represents a promising therapeutic strategy for reactivating p53's tumour-suppressive functions. This study explored the potential of ibutamoren (IBU) as a novel inhibitor of MDM2. In silico analyses utilizing molecular modelling revealed that IBU has a low IC50 for MDM2 inhibition and favourably binds to the p53-binding pocket of MDM2. In vitro experiments demonstrated that IBU treatment reduced the viability of immortalized cancer cell lines with a functional MDM2-p53 pathway but not in cell lines where this pathway harboured damaging mutations. This trend was further supported by RT-qPCR analysis, which showed differential expression of two p53 target genes upon IBU treatment in cell lines with wild MDM2-p53 pathways but not in those harbouring damaging mutations. These findings provide preliminary evidence supporting IBU's anticancer activity, plausibly through the MDM2-p53 pathway, and suggest that further studies are warranted to explore its mechanism of action and potential development as a lead compound in oncology research.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.